IMMUNOLOGICAL MECHANISMS IN CANCER PROGRAM The Immunological Mechanisms in Cancer Program comprises nineteen investigators from six academic departments. The primary objectives of the IMC Program are 1) to create a strong, intellectual and highly interactive scientific environment in which the functioning of the immune system as it relates to the cancer problem can be imaginatively and efficiently investigated;and 2) to foster, through intra- and inter-programmatic collaboration, the translation of the knowledge gained from these studies to the development of approaches for the prevention, diagnosis and treatment of cancer. The interests of the faculty are varied but the program is unified by four main themes: 1) to improve our understanding of the molecular and cellular basis for the development hematopoietic malignancies;2) to elucidate the nature of tumor antigen recognition and response to tumors by the immune system, thereby supporting development of immunotherapeutic approaches to cancer;3) to investigate the role of viruses in the development of cancer and cancer therapies;and 4) to create improvements in bone marrow transplantation approaches for the treatment of hematopoietic malignancies. Of the nineteen program members, eighteen have been funded through peer-reviewed awards. Current NCI and total peer review support for this program total approximately 1.8 and 8.2 million dollars, respectively. In the previous funding period, program members published 150 cancer-relevant papers, 14 and 20 percent of which resulted from intra, and inter-programmatic collaborations, respectively. Collaborations between members of this and other programs in the Kimmel Cancer Center have contributed to the production of reagents and analysis of preclinical models for testing novel therapies that have resulted in clinical trials. The expertise and the insight provided by members of the program is of increasing importance to the center for the definition of both functional and molecular aspects of the host-tumor interaction. Further development of the program is planned in the areas of tumor immunology and the immunobiology of dendritic cells.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA056036-13
Application #
8378859
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2012-06-01
Budget End
2013-05-31
Support Year
13
Fiscal Year
2012
Total Cost
$25,633
Indirect Cost
$8,982
Name
Thomas Jefferson University
Department
Type
DUNS #
053284659
City
Philadelphia
State
PA
Country
United States
Zip Code
19107
Rappaport, Jeffrey A; Waldman, Scott A (2018) The Guanylate Cyclase C-cGMP Signaling Axis Opposes Intestinal Epithelial Injury and Neoplasia. Front Oncol 8:299
Pandya, Kalgi D; Palomo-Caturla, Isabel; Walker, Justin A et al. (2018) An Unmutated IgM Response to the Vi Polysaccharide of Salmonella Typhi Contributes to Protective Immunity in a Murine Model of Typhoid. J Immunol 200:4078-4084
Hussain, Maha; Daignault-Newton, Stephanie; Twardowski, Przemyslaw W et al. (2018) Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol 36:991-999
Shafi, Ayesha A; Schiewer, Matthew J; de Leeuw, Renée et al. (2018) Patient-derived Models Reveal Impact of the Tumor Microenvironment on Therapeutic Response. Eur Urol Oncol 1:325-337
Meyer, Sara E; Muench, David E; Rogers, Andrew M et al. (2018) miR-196b target screen reveals mechanisms maintaining leukemia stemness with therapeutic potential. J Exp Med 215:2115-2136
Mazina, Olga M; Mazin, Alexander V (2018) Reconstituting the 4-Strand DNA Strand Exchange. Methods Enzymol 600:285-305
Magee, Michael S; Abraham, Tara S; Baybutt, Trevor R et al. (2018) Human GUCY2C-Targeted Chimeric Antigen Receptor (CAR)-Expressing T Cells Eliminate Colorectal Cancer Metastases. Cancer Immunol Res 6:509-516
Chervoneva, Inna; Freydin, Boris; Hyslop, Terry et al. (2018) Modeling qRT-PCR dynamics with application to cancer biomarker quantification. Stat Methods Med Res 27:2581-2595
Capparelli, Claudia; Purwin, Timothy J; Heilman, Shea A et al. (2018) ErbB3 Targeting Enhances the Effects of MEK Inhibitor in Wild-Type BRAF/NRAS Melanoma. Cancer Res 78:5680-5693
Nevler, Avinoam; Muller, Alexander J; Cozzitorto, Joseph A et al. (2018) A Sub-Type of Familial Pancreatic Cancer: Evidence and Implications of Loss-of-Function Polymorphisms in Indoleamine-2,3-Dioxygenase-2. J Am Coll Surg 226:596-603

Showing the most recent 10 out of 807 publications